Which has stronger earnings and valuation, VSTM or FBIO?

Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 11.97 -$209.47M -$2.70 N/A Fortress Biotech $63.26M 1.66 $6.82M $3.17 1.00

Is VSTM or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Verastem's net margin of -391.17%. Fortress Biotech's return on equity of 109.66% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Fortress Biotech 193.12% 109.66% 45.56%

Does the media favor VSTM or FBIO?

In the previous week, Verastem had 8 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Verastem and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Verastem's score of -0.02 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VNDA or FBIO?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 1 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FBIO or SABS?

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.50 beat Fortress Biotech's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBIO or CDXS more profitable?

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Codexis -40.97% -68.09% -23.72%

Does the media refer more to FBIO or CDXS?

In the previous week, Codexis had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Codexis and 1 mentions for Fortress Biotech. Codexis' average media sentiment score of 0.20 beat Fortress Biotech's score of 0.00 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AGEN or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Fortress Biotech 193.12% 109.66% 45.56%

Does the media prefer AGEN or FBIO?

In the previous week, Agenus and Agenus both had 1 articles in the media. Agenus' average media sentiment score of 0.90 beat Fortress Biotech's score of 0.00 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fortress Biotech (FBIO) Competitors

$3.16 +0.08 (+2.60%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$3.26 +0.10 (+3.13%)

As of 07:29 AM Eastern

Compare

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

Should you buy Fortress Biotech stock or one of its competitors? MarketBeat compares Fortress Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fortress Biotech include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), SAB Biotherapeutics (SABS), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.

How does Fortress Biotech compare to Verastem?

Verastem (NASDAQ:VSTM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Verastem has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	11.97	-$209.47M	-$2.70	N/A
Fortress Biotech	$63.26M	1.66	$6.82M	$3.17	1.00

88.4% of Verastem shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Verastem had 8 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Verastem and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Verastem's score of -0.02 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has a net margin of 193.12% compared to Verastem's net margin of -391.17%. Fortress Biotech's return on equity of 109.66% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Fortress Biotech	193.12%	109.66%	45.56%

Verastem currently has a consensus price target of $14.20, suggesting a potential upside of 237.29%. Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 437.97%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Verastem on 12 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 140.34%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 437.97%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 1 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.66	-$220.47M	-$4.05	N/A
Fortress Biotech	$63.26M	1.66	$6.82M	$3.17	1.00

Fortress Biotech has a net margin of 193.12% compared to Vanda Pharmaceuticals' net margin of -109.99%. Fortress Biotech's return on equity of 109.66% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Fortress Biotech	193.12%	109.66%	45.56%

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Fortress Biotech compare to SAB Biotherapeutics?

Fortress Biotech (NASDAQ:FBIO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Fortress Biotech currently has a consensus target price of $17.00, indicating a potential upside of 437.97%. SAB Biotherapeutics has a consensus target price of $11.88, indicating a potential upside of 206.85%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Fortress Biotech has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.50 beat Fortress Biotech's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics has lower revenue, but higher earnings than Fortress Biotech. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.66	$6.82M	$3.17	1.00
SAB Biotherapeutics	$1.32M	224.17	$13.27M	-$2.11	N/A

Fortress Biotech has a net margin of 193.12% compared to SAB Biotherapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

Fortress Biotech beats SAB Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Codexis?

Fortress Biotech (NASDAQ:FBIO) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Codexis	-40.97%	-68.09%	-23.72%

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 437.97%. Codexis has a consensus price target of $5.00, indicating a potential upside of 109.21%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fortress Biotech has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.66	$6.82M	$3.17	1.00
Codexis	$78.09M	2.78	-$43.97M	-$0.37	N/A

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fortress Biotech has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Codexis has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market.

In the previous week, Codexis had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Codexis and 1 mentions for Fortress Biotech. Codexis' average media sentiment score of 0.20 beat Fortress Biotech's score of 0.00 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Codexis on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Agenus?

Agenus (NASDAQ:AGEN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Fortress Biotech	193.12%	109.66%	45.56%

Agenus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Fortress Biotech has lower revenue, but higher earnings than Agenus. Fortress Biotech is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.12	$120K	$1.59	1.93
Fortress Biotech	$63.26M	1.66	$6.82M	$3.17	1.00

Agenus presently has a consensus price target of $23.00, indicating a potential upside of 649.19%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 437.97%. Given Agenus' higher possible upside, research analysts plainly believe Agenus is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

61.5% of Agenus shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Agenus and Agenus both had 1 articles in the media. Agenus' average media sentiment score of 0.90 beat Fortress Biotech's score of 0.00 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Agenus on 10 of the 15 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$102.32M	$3.45B	$6.45B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	1.00	19.75	24.66	23.99
Price / Sales	1.66	330.35	526.33	107.23
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.58	8.29	10.72	6.50
Net Income	$6.82M	$23.85M	$3.56B	$336.88M
7 Day Performance	2.93%	2.87%	0.94%	-0.16%
1 Month Performance	15.33%	2.19%	0.36%	0.76%
1 Year Performance	76.54%	55.48%	29.67%	28.49%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.0712 of 5 stars	$3.16 +2.6%	$17.00 +438.0%	+84.8%	$102.32M	$63.26M	1.00	170
VSTM Verastem	2.516 of 5 stars	$4.25 +3.2%	$15.60 +267.1%	-8.9%	$362.04M	$30.91M	N/A	50	News Coverage Analyst Forecast
VNDA Vanda Pharmaceuticals	1.839 of 5 stars	$6.00 +3.4%	$14.30 +138.3%	+33.1%	$348.78M	$216.10M	N/A	290	News Coverage
SABS SAB Biotherapeutics	3.3324 of 5 stars	$3.93 -1.8%	$11.88 +202.2%	+119.9%	$305.86M	$1.32M	N/A	140	Gap Up
CDXS Codexis	2.4418 of 5 stars	$2.37 -7.8%	$5.00 +111.0%	+1.3%	$233.60M	$70.39M	N/A	250	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

How does Fortress Biotech compare to Verastem?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Summary

How does Fortress Biotech compare to Codexis?

Summary

How does Fortress Biotech compare to Agenus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

How does Fortress Biotech compare to Verastem?

Which has more volatility & risk, VSTM or FBIO?

Which has stronger earnings and valuation, VSTM or FBIO?

Do insiders & institutionals hold more shares of VSTM or FBIO?

Does the media favor VSTM or FBIO?

Is VSTM or FBIO more profitable?

Do analysts prefer VSTM or FBIO?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Do analysts prefer VNDA or FBIO?

Does the media prefer VNDA or FBIO?

Which has preferable earnings and valuation, VNDA or FBIO?

Is VNDA or FBIO more profitable?

Do insiders and institutionals hold more shares of VNDA or FBIO?

Which has more volatility and risk, VNDA or FBIO?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Do insiders & institutionals have more ownership in FBIO or SABS?

Do analysts prefer FBIO or SABS?

Which has more volatility & risk, FBIO or SABS?

Does the media refer more to FBIO or SABS?

Which has preferable valuation and earnings, FBIO or SABS?

Is FBIO or SABS more profitable?

Summary

How does Fortress Biotech compare to Codexis?

Is FBIO or CDXS more profitable?

Do analysts prefer FBIO or CDXS?

Which has stronger earnings & valuation, FBIO or CDXS?

Do insiders and institutionals have more ownership in FBIO or CDXS?

Which has more risk and volatility, FBIO or CDXS?

Does the media refer more to FBIO or CDXS?

Summary

How does Fortress Biotech compare to Agenus?

Is AGEN or FBIO more profitable?

Which has more volatility and risk, AGEN or FBIO?

Which has preferable valuation and earnings, AGEN or FBIO?

Do analysts recommend AGEN or FBIO?

Do institutionals and insiders believe in AGEN or FBIO?

Does the media prefer AGEN or FBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools